INVO Bioscience, Inc. (INVO) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, filed on August 14, 2024, by INVO Bioscience, Inc. (a Nevada corporation), serves as a current report to announce the issuance of a press release regarding financial results for the period ended June 30, 2024. The company's common stock trades on The Nasdaq Stock Market LLC under the symbol "INVO."
Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results are contained within the attached press release (Exhibit 99.1), which is furnished but not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Material Changes
No material changes versus prior periods are detailed in the text of this Form 8-K. The filing solely references the announcement of results for the period ended June 30, 2024, without providing comparative data or analysis within the body of the report.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It explicitly states that the information in Item 2.02 and Exhibit 99.1 shall not be incorporated by reference into any other Company filing unless expressly stated.
Key Facts for Investor Verification
- Verify the specific financial results for the period ended June 30, 2024, by reviewing Exhibit 99.1 (Press Release dated August 14, 2024), as the 8-K text does not contain the data.
- Note that the financial information in this filing is furnished and not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
- Confirm the company's status as an emerging growth company (indicated as not applicable in the filing) and its listing on Nasdaq.